We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dual Gene Activation Characterizes Breast Tumors

By Biotechdaily staff writers
Posted on 14 Nov 2006
Cancer researchers have shown that the uPAR gene is overexpressed primarily in the same breast cancer cells that overexpress another cancer gene, HER-2, adding another potential target for chemotherapeutic attack.

uPAR is a component of the plasminogen activation system, which in the healthy body is involved in tissue reorganization events such as mammary gland involution and wound healing. More...
In order to be able to reorganize tissue, it is necessary that the old tissue be degraded. An important mechanism in this degradation is the proteolysis cascade initiated by the plasminogen activation system. uPAR binds urokinase, thereby restricting plasminogen activation to the immediate vicinity of the cell membrane. The components of the plasminogen activation system have been found to be highly expressed in many malignant tumors, indicating that tumors are able to subvert the system and use it to drive metastasis.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) analyzed both individual tumor cells (the type that escape from the tumor into the circulation system) and cancerous tissues.

They reported in the November 1, 2006, online edition of the Proceedings of the [U.S.] National Academy of Sciences that analysis of individual tumor cells indicated that uPAR amplification occurred in a significant portion of primary breast cancers. There was complete concordance between touch preps and conventional pathologic examination of HER-2 and uPAR gene status in primary tumors. There was also excellent concordance of HER-2 gene status between primary tumors and circulating tumor cells provided that acquisition of HER-2 gene amplification in the circulating tumor cells was taken into account. Unexpectedly, gene amplification of HER-2 and uPAR occurred most frequently in the same tumor cells and patients, suggesting a biologic bias and potential advantage for co-amplification. Expression of HER-2 and uPAR in primary tumors predicted gene status in 100% and 92% of patients, respectively.

"This gene, uPAR, is an important oncogene, and that is why we determined whether or not it is amplified,” explained senior author Dr. Jonathon Uhr, professor of cancer immunobiology at the University of Texas Southwestern Medical Center.

"Unexpectedly, it is usually amplified in the same tumor cell with HER-2 gene amplification. This has significant implications for treatment with targeting agents. Moreover, we stress the value of individual tumor cell analysis for providing information that cannot be obtained by conventional pathological examination.”



Related Links:
University of Texas Southwestern Medical Center

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Thyroid Test
Anti-Thyroid EIA Test
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.